Does HER2 status influence locoregional failure rates in breast cancer patients treated with mastectomy for pT1-2pN0 disease?

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 988-993

  Kwan, W ^a   Al Tourah, A J ^a   Speers, C ^b   Woods, R ^b   Kennecke, H ^c   Olivotto, I A ^d  

^a Fraser Valley Centre   (Canada)

^b Breast Cancer Outcomes Unit   (Canada)

^c Vancouver Centre   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Breast cancer; HER2 status; Locoregional control

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MASTECTOMY, MODIFIED RADICAL; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77953339510     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp396     Document Type: Article

References (23)

1. Ross JS, Fletcher JA, Linette GP et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-325.
2. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004; 9: 606-616.
3. Chia S, Norris B, Cheang M et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008; 26(35): 5697-5704.
4. Ragaz J, Olivotto IA, Spinelli JJ et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005; 97: 116-126.
5. Overgaard M, Hansen PS, Overgaard J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949-955.
6. Clarke M, Collins R, Darby S et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-2106.
7. Harris JR, Halpin-Murphy P, McNeese M et al. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44: 989-990.
8. Truong PT, Olivotto IA, Whelan TJ et al. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy 2004; 170: 1263-1273.
9. Recht A, Edge SB, Solin LJ et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1539-1569.
10. Truong PT, Lesperance M, Culhaci A et al. Patient subsets with T1-T2, node negative breast cancer at high locoregional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys 2005; 62: 175-182.
11. Jagsi R, Raad RA, Goldberg S et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys 2005; 62: 1035-1039.
12. Cheang MC, Treaba DO, Speers CH et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 2006; 24: 5637-5644.
13. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25(1): 118-145.
14. Buchholz TA, Huang EH, Berry D et al. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 1337-1342.
15. Pietras RJ, Poen JC, Gallardo D et al. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999; 59: 1347-1355.
16. Harris EE, Hwang WT, Lee EA et al. The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy. Breast J 2006; 12: 431-436.
17. Gabos Z, Thoms J, Hanson J. The prognostic significance of human epidermal growth factor receptor-2 over-expression for the development of local recurrence after newly diagnosed breast cancer. In Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December, 2007; (Abstr 1060).
18. Paik S, Hazan R, Fisher ER et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103-112.
19. Fisher B, Anderson S, Redmond CK et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333(22): 1456-1461.
20. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347(16): 1233-1241.
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659-1672.
22. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1673-1684.
23. Kyndi M, Sorensen FB, Knudsen H et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 1419-1426.